TTrialPathMatch Me to Trials
← Back to trials
RecruitingColonic PolypSedation Complication

A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy

Eligible age

18–60 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this prospective, randomized, controlled study is to compare remimazolam besilat/sufentanyl and propofol/sufentanyl in patients during colonoscopic polypectomies procedures. Patients undergoing colonoscopic polypectomies in procedural sedation using remimazolam besylate/sufentanyl are circulatory and respiratory as or more stable when compared with propofol/sufentanyl sedation.

Sponsor: Clinical Hospital Centre Zagreb

You may qualify if…

  • ✓ Patients both male and female
  • ✓ ages 18 to 60 years,
  • ✓ with one or more colonic polyps confirmed by colonoscopy and scheduled for a colonoscopy and polypectomy
  • ✓ The duration of the colonoscopy ranges from 30 to 50 minutes.
  • ✓ ASA status (American Society of Anaesthesiologists physical status) I-III.
  • ✓ BMI (Body mass index) 18.5-29.9 kg/m2.
  • ✓ Only patients who signed an informed consent waiver and consented to participate in the research study.

You may not qualify if…

  • ✕ Patients aged \>60 years
  • ✕ ASA status IV-V,
  • ✕ BMI \>29.9 kg/m2,
  • ✕ a high risk of vomiting, regurgitation and/or aspiration of gastric contents.
  • ✕ Patients with:
  • ✕ uncontrolled hypertension (systolic pressure \>160 mmHg),
  • ✕ heart disease (cardiomyopathy, cardiac-rhythm disorder, left ventricular ejection fraction \<45%, stenosis or heart valve insufficiency and coronary heart disease)
  • ✕ lung disease (pneumonia, chronic obstructive pulmonary disease, asthma and pulmonary tumors),

Source: ClinicalTrials.gov · NCT07456111 · last updated 2026-03-06